Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.
Results establish 15 and 17 as promising ENPP1 inhibitors with favorable safety profiles, supporting their potential in combination cancer immunotherapy.